ER+ Breast Cancers Resistant to Prolonged Neoadjuvant Letrozole Exhibit an E2F4 Transcriptional Program Sensitive to CDK4/6 Inhibitors-Reference-Cited by-同舟云学术

ER+ Breast Cancers Resistant to Prolonged Neoadjuvant Letrozole Exhibit an E2F4 Transcriptional Program Sensitive to CDK4/6 Inhibitors

Published:2018-03-26 Issue:11 Volume:24 Page:2517-2529
ISSN:1078-0432
Container-title:Clinical Cancer Research
language:en
Short-container-title:Clin Cancer Res

Author:

Guerrero-Zotano Angel L.,Stricker Thomas P.,Formisano Luigi,Hutchinson Katherine E.^ORCID,Stover Daniel G.,Lee Kyung-Min,Schwarz Luis J.,Giltnane Jennifer M.,Estrada Monica V.^ORCID,Jansen Valerie M.,Servetto Alberto,Gavilá Joaquín,Perez-Fidalgo J. Alejandro,Lluch Ana,Llombart-Cussac Antonio,Bayar Mohamed Amine^ORCID,Michiels Stefan,André Fabrice,Arnedos Mónica,Guillem Vicente,Ruiz-Simon Amparo,Arteaga Carlos L.

Funder

Asociación Española Contra el Cáncer

Sociedad Española Oncología Médica

Publisher

American Association for Cancer Research (AACR)

Subject

Cancer Research,Oncology

Cited by 28 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Secondary Analysis of Human Bulk RNA-Seq Dataset Suggests Potential Mechanisms for Letrozole Resistance in Estrogen-Positive (ER+) Breast Cancer;Current Issues in Molecular Biology;2024-07-06

2. Resistance to Endocrine Therapy in Breast Cancer;Overcoming Breast Cancer Therapy Resistance;2024

3. A micro-flow, high-pH, reversed-phase peptide fractionation and collection system for targeted and in-depth proteomics of low-abundance proteins in limiting samples;MethodsX;2023-12

4. The MonarchE trial: improving the clinical outcome in HR⁺/HER2⁻ early breast cancer: recent results and next steps;Cancer Communications;2023-07-18

5. Prognostic and Predictive Value of LIV1 Expression in Early Breast Cancer and by Molecular Subtype;Pharmaceutics;2023-03-14